A retrospective observational study of changes in uterine fibroid blood flow and fibroid diameter after administration of gonadotropin-releasing hormone agonists and antagonists using superb microvascular imaging

IF 1.6 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research Pub Date : 2025-07-03 DOI:10.1111/jog.16361

Yudai Tanaka, Hiroaki Fujita, Reiko Kitayama, Minako Katano, Eri Nakano, Naoki Yoshikawa, Aya Shiraiwa, Kana Hirayama, Akane Takaya, Reiko Numazaki, Yuki Furusawa, Yoshihiro Nishijima, Eri Obiya

{"title":"A retrospective observational study of changes in uterine fibroid blood flow and fibroid diameter after administration of gonadotropin-releasing hormone agonists and antagonists using superb microvascular imaging","authors":"Yudai Tanaka, Hiroaki Fujita, Reiko Kitayama, Minako Katano, Eri Nakano, Naoki Yoshikawa, Aya Shiraiwa, Kana Hirayama, Akane Takaya, Reiko Numazaki, Yuki Furusawa, Yoshihiro Nishijima, Eri Obiya","doi":"10.1111/jog.16361","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>The relationship between the changes in fibroid blood flow and fibroid diameter during the administration of GnRH agonists and antagonists was examined using superb microvascular imaging (SMI).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Changes in the maximum fibroid blood flow and diameter at weeks 0, 2, 4, and 8 were compared between the relugolix, a GnRH antagonist, and leuprolide, a GnRH agonist, groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Data were collected for 16 fibroids from 12 patients in the relugolix group and 12 fibroids from 9 patients in the leuprorelin group. A significant decrease was observed in the fibroid diameter at 8 weeks in the relugolix group, but no significant change was observed at any time point in the leuprorelin group. In the relugolix group, a significant correlation were observed between changes in blood flow at 2 weeks and fibroid diameter changes at 2 and 4 weeks, and between changes in blood flow at 4 weeks and fibroid diameter changes at 4 weeks. No significant correlation was observed in the leuprorelin group.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In the treatment of uterine fibroids with relugolix, a reduction in fibroid blood flow assessed by SMI may suggest a subsequent reduction in fibroid size. These results provide useful insights when making the decision whether or not to continue relugolix administration.</p>\n </section>\n </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 7","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jog.16361","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynaecology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jog.16361","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

The relationship between the changes in fibroid blood flow and fibroid diameter during the administration of GnRH agonists and antagonists was examined using superb microvascular imaging (SMI).

Methods

Changes in the maximum fibroid blood flow and diameter at weeks 0, 2, 4, and 8 were compared between the relugolix, a GnRH antagonist, and leuprolide, a GnRH agonist, groups.

Results

Data were collected for 16 fibroids from 12 patients in the relugolix group and 12 fibroids from 9 patients in the leuprorelin group. A significant decrease was observed in the fibroid diameter at 8 weeks in the relugolix group, but no significant change was observed at any time point in the leuprorelin group. In the relugolix group, a significant correlation were observed between changes in blood flow at 2 weeks and fibroid diameter changes at 2 and 4 weeks, and between changes in blood flow at 4 weeks and fibroid diameter changes at 4 weeks. No significant correlation was observed in the leuprorelin group.

Conclusion

In the treatment of uterine fibroids with relugolix, a reduction in fibroid blood flow assessed by SMI may suggest a subsequent reduction in fibroid size. These results provide useful insights when making the decision whether or not to continue relugolix administration.

Abstract Image

查看原文本刊更多论文

应用高超微血管成像技术观察促性腺激素释放激素激动剂和拮抗剂对子宫肌瘤血流和肌瘤直径的影响

目的应用超精细微血管成像技术（SMI）研究GnRH激动剂和拮抗剂治疗期间肌瘤血流变化与肌瘤直径的关系。方法比较GnRH拮抗剂relugolix组和GnRH激动剂leuprolide组在第0、2、4、8周子宫肌瘤最大血流量和直径的变化。结果收集了12例患者的16个肌瘤资料，雷洛维利组9例患者的12个肌瘤资料。在8周时，雷洛维利组肌瘤直径明显减小，但在任何时间点，雷洛维林组均未观察到明显变化。在relugolix组中，2周血流变化与2周和4周肌瘤直径变化之间，以及4周血流变化与4周肌瘤直径变化之间存在显著相关性。leuprorelin组无显著相关性。结论在使用瑞路高利治疗子宫肌瘤时，SMI评估的肌瘤血流量减少可能提示肌瘤尺寸减小。这些结果为决定是否继续使用relugolix提供了有用的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Obstetrics and Gynaecology Research 医学-妇产科学

CiteScore

3.10

自引率

0.00%

发文量

376

审稿时长

3-6 weeks

期刊介绍： The Journal of Obstetrics and Gynaecology Research is the official Journal of the Asia and Oceania Federation of Obstetrics and Gynecology and of the Japan Society of Obstetrics and Gynecology, and aims to provide a medium for the publication of articles in the fields of obstetrics and gynecology. The Journal publishes original research articles, case reports, review articles and letters to the editor. The Journal will give publication priority to original research articles over case reports. Accepted papers become the exclusive licence of the Journal. Manuscripts are peer reviewed by at least two referees and/or Associate Editors expert in the field of the submitted paper.